Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Hepatitis B | Guidelines

Clinical practice guideline management of blood borne viruses within the haemodialysis unit

Authors: Elizabeth Garthwaite, Veena Reddy, Sam Douthwaite, Simon Lines, Kay Tyerman, James Eccles

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Some people who are receiving dialysis treatment have virus infection such as hepatitis B, hepatitis C and/or HIV that is present in their blood. These infections can be transmitted to other patients if blood is contaminated by the blood of another with a viral infection. Haemodialysis is performed by passing blood from a patient through a dialysis machine, and multiple patients receive dialysis within a dialysis unit. Therefore, there is a risk that these viruses may be transmitted around the dialysis session. This documents sets out recommendations for minimising this risk.
There are sections describing how machines and equipment should be cleaned between patients. There are also recommendations for dialysing patients with hepatitis B away from patients who do not have hepatitis B. Patients should be immunised against hepatitis B, ideally before starting dialysis if this is possible. There are guidelines on how and when to do this, for checking whether immunisation is effective, and for administering booster doses of vaccine. Finally there is a section on the measures that should be taken if a patient receiving dialysis is identified as having a new infection of hepatitis B, hepatitis C or HIV.
Appendix
Available only for authorised users
Literature
1.
2.
Report of the Rosenheim Advisory Group. Hepatitis and the treatment of chronic renal failure. Scottish Home and Health Department, Welsh Office: Department of Health and Social Security; 1972.
3.
Recommendations of a working group convened by the Public Health Laboratory Service (PHLS) on behalf of the Department of Health. Good Practice Guidelines for Renal Dialysis/Transplantation Units. Prevention and control of blood-borne virus infection. 2002.
4.
Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18:52–61.PubMedCrossRef
5.
Byrne C, Caskey F, Castledine C, Dawnay A, Ford D, Fraser S, Lambie M, Maxwell H, Steenkamp R, Wilkie M, Williams AJ. All patients receiving renal replacement therapy in the United Kingdom 2015. In: NEPHRON 2017;137 (suppl1) UK renal registry; 19th annual report of the renal association. UK Renal Registry, Bristol, UK.
6.
Teles SA, Martins RM, Vanderborght B, Stuyver L, Gaspar AM, Yoshida CF. Hepatitis B virus: genotypes and subtypes in Brazilian hemodialysis patients. Artif Organs. 1999;23:1074–8.PubMedCrossRef
7.
Spada E, Abbate I, Sicurezza E, et al. Molecular epidemiology of a hepatitis C virus outbreak in a hemodialysis unit in Italy. J Med Virol. 2008;80:261–7.PubMedCrossRef
8.
Castell J, Gutierrez G, Castell J, Gutierrez G. Outbreak of 18 cases of hepatitis C in a hemodialysis unit. [Spanish]. Gac Sanit. 2005;19:214–20.PubMedCrossRef
9.
Ramalingam S, Leung T, Cairns H, et al. Transmission of hepatitis B virus (genotype E) in a haemodialysis unit. J Clin Virol. 2007;40:105–9.PubMedCrossRef
10.
Kondili LA, Genovese D, Argentini C, et al. Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. Eur J Clin Microbiol Infect Dis. 2006;25:527–31.PubMedCrossRef
11.
Irish DN, Blake C, Christophers J, et al. Identification of hepatitis C virus seroconversion resulting from nosocomial transmission on a haemodialysis unit: implications for infection control and laboratory screening. J Med Virol. 1999;59:135–40.PubMedCrossRef
12.
Masuko K, Mitsui T, Iwano K, et al. Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N Engl J Med. 1996;334:1485–90.PubMedCrossRef
13.
Schlaak JF, Kohler H, Gerken G. Hepatitis G virus: an old, but newly discovered hepatotropic virus--is it of interest for the nephrologist? Nephrol Dial Transplant. 1996;11:1522–3.PubMed
14.
Hosseini-Moghaddam SM, Keyvani H, Samadi M, Alavian SM, Mahdavimazdeh M, Daneshvar S, Razzaghi Z. GB virus type C infection in hemodialysis patients considering co-infection with hepatitis C virus. J Med Virol. 2008;80(7):1260–3.PubMedCrossRef
15.
16.
El Sayed NM, Gomatos PJ, Beck-Sague CM, et al. Epidemic transmission of human immunodeficiency virus in renal dialysis centers in Egypt. J Infect Dis. 2000;181(1):91–7.PubMedCrossRef
17.
Good T, et al. Nosocomial transmission of hepatitis C virus within a British dialysis Centre. Nephrol Dial Transplant. 1997;12:304–9.PubMedCrossRef
18.
Hmaied F, Ben Mamou M, Saune-Sandres K, et al. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J Med Virol. 2006;78:185–91.PubMedCrossRef
19.
Sartor C, Brunet P, Simon S, et al. Transmission of hepatitis C virus between hemodialysis patients sharing the same machine. Infect Control Hosp Epidemiol. 2004;25:609–11.PubMedCrossRef
20.
Stragier A, Jadoul M. Should dialysis machines be disinfected between patients' shifts? EDTNA ERCA J. 2003;29:73–6.PubMedCrossRef
21.
Wheeler D, Winkelmayer WC. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int. 2008;73:S1–S99.
22.
Karkar A, Abdelrahman M, Ghacha R, et al. Prevention of viral transmission in HD units: the value of isolation. Nasrat Amrad Wa Ziraat Alkulat. 2006;17:183–8.
23.
Marcus R, Favero MS, Banerjee S, et al. Prevalence and incidence of human immunodeficiency virus among patients undergoing long-term hemodialysis. The cooperative Dialysis study group. Am J Med. 1991;90:614–9.PubMedCrossRef
24.
Jadoul M, Cornu C, van Ypersele dS, Jadoul M, Cornu C, Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian multicenter study. The Universitaires Cliniques St-Luc (UCL) collaborative group. Kidney Int. 1998;53:1022–5.PubMedCrossRef
25.
26.
27.
28.
Favero MS, Maynard JE, Petersen NJ, et al. Letter: Hepatitis-B antigen on environmental surfaces. Lancet. 1973;2:1455.PubMedCrossRef
29.
Froio N, Nicastri E, Comandini UV, et al. Contamination by hepatitis B and C viruses in the dialysis setting. Am J Kidney Dis. 2003;42:546–50.PubMedCrossRef
30.
AlFurayh O, Sabeel A, Al Ahdal MN, et al. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. Am J Nephrol. 2000;20:103–6.PubMedCrossRef
31.
Kroes AC, van Bommel EF, Niesters HG, Weimar W. Hepatitis B viral DNA detectable in dialysate. Nephron. 1994;67:369.PubMedCrossRef
32.
Valtuille R, Fernandez JL, Berridi J, et al. Evidence of hepatitis C virus passage across dialysis membrane. Nephron. 1998;80:194–6.PubMedCrossRef
33.
Lindley E, Boyle G, Gandy D, et al. How plausible is hepatitis C virus via the haemodialysis circuit. NDT Plus. 2011;4:434–6.PubMedPubMedCentral
34.
Wheeler D, Winkelmayer WC. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int. 2018;8:S91–S165.
35.
Petrosillo N, Gilli P, Serraino D, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis.[see comment]. Am J Kidney Dis. 2001;37:1004–10.PubMedCrossRef
36.
Saxena AK, Panhotra BR. The impact of nurse understaffing on the transmission of hepatitis C virus in a hospital-based hemodialysis unit. Med Princ Pract. 2004;13:129–35.PubMedCrossRef
37.
Kroes AC, van Bommel EF, Kluytmans JA, et al. Hepatitis B and hemodialysis: the impact of universal precautions in preventing the transmission of bloodborne viruses. Infect Control Hosp Epidemiol. 1998;19:508–10.PubMedCrossRef
38.
39.
CDC. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR. 2001;50:RR-5.
40.
Alter MJ, Ahtone J, Maynard JE. Hepatitis B virus transmission associated with a multiple-dose vial in a hemodialysis unit. Ann Intern Med. 1983;99:330–3.PubMedCrossRef
41.
Kokubo S, Horii T, Yonekawa O, Ozawa N, Mukaide M. A phylogenetictree analysis elucidating nosocomial transmission of hepatitis C virus in a haemodialysis unit. J Viral Hepat. 2002;9:450–4.PubMedCrossRef
42.
Fabrizi F, Messa P. Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015;38:471–80.PubMedCrossRef
43.
Lanini S, Puro V, Lauria F, Fusco F, Nisii C, Ippolito G. Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. BMC Med. 2009;7:15.PubMedPubMedCentralCrossRef
44.
Tokars JI, Finelli L, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2001. Semin Dial. 2004;17:310–9.PubMedCrossRef
45.
46.
Moloughney BW. Transmission and postexposure management of blood borne virus infections in the health care setting: where are we now? CMAJ. 2001;165:445–51.PubMedPubMedCentral
47.
Froio N, Nicastri E, Comandini U, et al. Contamination of hepatitis B and C viruses in the dialysis setting. Am J Kidney Dis. 2003;42:546–50.PubMedCrossRef
48.
Favero M, Tokars J, Arduino M, et al. Nosocomial infections associated with hemodialysis. In: Mayall CG, editor. Hospital Epidemiology and Infection Controled 2. Philadelphia: Lippincott Williams and Wilkens; 1999. p. 897–917.
49.
Alter M, Favero M, Maynard J. Impact of infection control strategies on the incidence of dialysis- associated hepatitis in the United States. J Infect Dis. 1986;153:1149–51.PubMedCrossRef
50.
Tokars JI, Alter MJ, Miller E, Moyer LA, Favero MS. National surveillance of dialysis associated diseases in the United States; 1994.
51.
European Best Practice Guidelines for Haemodialysis (part 1). Guideline V1.6: prevention and management of HBV, HCV and HIV in HD patients. Nephrol Dial Transplant. 2002;17(Suppl 7):78–81.
52.
Bravo Zuniga JI, Loza Munarriz C, Lopez-Alcalde J. Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units. Cochrane Database Syst Rev. 2016;8:CD006420.
53.
Thomson P, Williams C, Aitken C, et al. A case of hepatitis C virus transmission acquired through sharing a haemodialysis machine. NDT Plus. 2011;4:32–5.PubMed
54.
55.
U.S. Department of Health and Human Services. Centers for Disease Control and Prevention (CDC). Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50:1.
56.
Marcus R, Favero MS, Banerjee S, et al. Prevalence and incidence of human immunodeficiency virus among patients undergoing longterm hemodialysis. The cooperative Dialysis study group. Am J Med. 1991;90:614–9.PubMedCrossRef
57.
Ahuja TS, O'brien WA. Special issues in the management of patients with ESRD and HIV infection. Am J Kidney Dis. 2003;41:279.PubMedCrossRef
58.
59.
Health Canada: Therapeutic Products Directorate. Notice to hospitals: Hemodialysis units and blood tubing sets incorporating a transducer protector. Health Canada [serial online] 2004;Accessed 2 Sept 2008.
60.
Brunet P, Frenkian G, Girard AM, et al. Backward flow of blood in the extracorporal circuit pressure transducers of the generator-monitors of hemodialysis. [French]. Nephrol Ther. 2005;1:157–60.PubMedCrossRef
61.
Delarocque-Astagneau E, Baffoy N, Thiers V, et al. Outbreak of hepatitis C virus infection in a hemodialysis unit: potential transmission by the hemodialysis machine? Infect Control Hosp Epidemiol. 2002;23:328–34.PubMedCrossRef
62.
Savey A, Simon F, Izopet J, et al. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center.[erratum appears in infect control Hosp Epidemiol. 2005 Oct; 26(10):810]. Infect Control Hosp Epidemiol. 2005;26:752–60.PubMedCrossRef
63.
Kroes AC, van Bommel EF, Niesters HG, Weimar W. Hepatitis B viral DNA detectable in dialysate. Nephron. 1994;67:369.PubMedCrossRef
64.
65.
Roll M, Norder H, Magnius LO, Grillner L, Lindgren V. Nosocomial spread of hepatitis B virus (HBV) in a haemodialysis unit confirmed by HBV DNA sequencing. J Hosp Infect. 1995;30:57–63.PubMedCrossRef
66.
Chaves SS, Daniels D, Cooper BW, et al. Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection. Vaccine. 2011;29(52):9618–23.PubMedCrossRef
67.
Minuk GY, Sun DF, Greenberg R, et al. Occult hepatitis B virus infection in a north American adult hemodialysis patient population. Hepatology. 2004;40:1072–7.PubMedCrossRef
68.
Saijo T, Joki N, Inishi Y, Muto M, Saijo M, Hase H. Occult hepatitis B virus infection in hemodialysis patients in Japan. Ther Apher Dial. 2015;1:125–30.CrossRef
69.
Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol. 2006;36(Suppl 1):S33–44.PubMedCrossRef
70.
Liu CJ, Kao JH, Chen DS. Molecular assays for hepatitis B virus infection. Hepatology. 2003;38:1311.PubMedCrossRef
71.
Rahnavardi M, Hosseini Moghaddam SM, Alavian SM. Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol. 2008;28:628–40.PubMedCrossRef
72.
Midgard H, Weir A, Palmateer N, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol. 2016;65:S33–45.PubMedCrossRef
73.
74.
Courouce AM, Le Marrec N, Bouchardeau F, et al. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion. 2000;40:1198–202.PubMedCrossRef
75.
Fabrizi F, de Vecchi AF, Como G, et al. De novo HCV infection among dialysis patients: a prospective study by HCV core antigen ELISA assay. Aliment Pharmacol Ther. 2005;21:861–9.PubMedCrossRef
76.
77.
Tokars JI, Alter MJ, Miller E, Moyer LA, Favero MS. National surveillance of dialysis associated diseases in the United States--1994. ASAIO J. 1997;43:108–19.PubMed
78.
Tokars JI, Alter MJ, Favero MS, Moyer LA, Bland LA. National surveillance of dialysis associated diseases in the United States, 1991. ASAIO J. 1993;39:966–75.PubMedCrossRef
79.
Hepatitis B in retreat from dialysis units in United Kingdom in 1973. Public health laboratory service survey. Br Med J. 1976;1:1579–81.
80.
Najem GR, Louria DB, Thind IS, et al. Control of hepatitis B infection. The role of surveillance and an isolation hemodialysis center. JAMA. 1981;245:153–7.PubMedCrossRef
81.
Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65:2335–42.PubMedCrossRef
82.
Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19:904–9.PubMedCrossRef
83.
Taal MW, Zyl-Smit R. Hepatitis C virus infection in chronic haemodialysis patients--relationship to blood transfusions and dialyser re-use. S Afr Med J. 2000;90:621–5.PubMed
84.
Fabrizi F, Messa P, Martin P. Transmission of hepatitis C virus infection in hemodialysis: current concepts. Int J Artif Organs. 2008;31(12):1004–16.PubMedCrossRef
85.
European Best Practice Guidelines for Haemodialysis (Part 1). Guideline VI.6: prevention and management of HBV, HCV and HIV in HD patients. Nephrol Dial Transplant. 2002;17(Suppl 7):78–81.
86.
Harmankaya O, Cetin B, Erimez D, et al. Patient isolation prevents the transmission of hepatitis C virus infection in hemodialysis units. Dial Transplant. 2002;31:859–61.
87.
Dzekova-Vidimliski P, Pavleska-Kuzmanovska S, Trajceska L, et al. Decreasing prevalence of hepatitis C virus infection in hemodialysis patients: Following KDIGO guidelines. Nephrol Dial Transplant. 2012;27(Suppl 2):ii294.
88.
Gallego E, Lopez A, Perez J, et al. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Pract. 2006;104:c1–6.PubMedCrossRef
89.
Shebeb AM, Kotkat AM, Abd El Reheim SM, et al. An intervention study for prevention of HCV infection in some hemodialysis units in Alexandria. J Egypt Public Health Assoc. 2006;81:119–41.PubMed
90.
Agarwal SK, Dash SC, Gupta S, et al. Hepatitis C virus infection in haemodialysis: the ‘no-isolation’ policy should not be generalized. Nephron Clin Pract. 2009;111:c133–40 (ref 18).PubMedCrossRef
91.
Allander T, Medin C, Jacobson SH, Grillner L, Persson MA. Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J Med Virol. 1994;43:415–9.PubMedCrossRef
92.
Simon N, Courouce AM, Lemarrec N, Trepo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int. 1994;46:504–11.PubMedCrossRef
93.
McLaughlin KJ, Cameron SO, Good T, et al. Nosocomial transmission of hepatitis C virus within a British dialysis Centre. Nephrol Dial Transplant. 1997;12:304–9.PubMedCrossRef
94.
Velandia M, Fridkin SK, Cardenas V, et al. Transmission of HIV in dialysis Centre. Lancet. 1995;345:1417–22.PubMedCrossRef
95.
El Sayed NM, Gomatos PJ, Beck-Sague CM, et al. Epidemic transmission of human immunodeficiency virus in renal dialysis centers in Egypt. J Infect Dis. 2000;181:91–7.PubMedCrossRef
96.
Shamshirsaz AA, Kamgar M, Bekheirnia MR, et al. The role of hemodialysis machines dedication in reducing Hepatitis C transmission in the dialysis setting in Iran: a multicenter prospective interventional study. BMC Nephrol. 2004;5:13.PubMedPubMedCentralCrossRef
97.
Saxena AK, Panhotra BR, Sundaram DS, et al. Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unit of the middle east. Am J Infect Control. 2003;31:26–33.PubMedCrossRef
98.
Stevens CE, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med. 1984;311:496–501.PubMedCrossRef
99.
Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis. 1999;33:356–60.PubMedCrossRef
100.
Cendoroglo NM, Draibe SA, Silva AE, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant. 1995;10:240–6.
101.
Lefebure AF, Verpooten GA, Couttenye MM, De Broe ME. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients. Vaccine. 1993;11(4):397–9.PubMedCrossRef
102.
Bel'eed K, Wright M, Eadington D, Farr M, Sellars L. Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J. 2002;78(923):538–40.PubMedPubMedCentralCrossRef
103.
Prince AM, Szmuness W, Mann MK, et al. Hepatitis B immune globulin: final report of a controlled, multicenter trial of efficacy in prevention of dialysis-associated hepatitis. J Infect Dis. 1978;137:131–44.PubMedCrossRef
104.
105.
Crosnier J, Jungers P, Courouce AM, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients. Lancet. 1981;1:797–800.PubMedCrossRef
106.
Crosnier J, Jungers P, Courouce AM, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, medical staff. Lancet. 1981;1:455–9.PubMedCrossRef
107.
Kohler H, Arnold W, Renschin G, Dormeyer HH, Meyer zum Buschenfelde KH. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int. 1984;25:124–8.PubMedCrossRef
108.
DaRoza G, Loewen A, Djurdjev O, et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis. 2003;42:1184–92.PubMedCrossRef
109.
Ridley L, Jones C. An audit of a programme of proactive pre-dialysis vaccination against hepatitis B., . [Abstract]Ridley L, Jones C. British Renal Congress 2008; Glasgow, May 2008.
110.
Seaworth B, Drucker J, Starling J, et al. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis. 1988;157:332–7.PubMedCrossRef
111.
Grzegorzewska, Alicja E. “Hepatitis B Vaccination in Chronic Kidney Disease: Review of Evidence in Non-Dialyzed Patients.” Hepatitis Monthly 12.11 (2012): e7359. PMC. Web. 6 Dec. 2017.
112.
Agarwal SK, Irshad M, Dash SC. Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure. J Assoc Physicians India. 1999;47(2):183–5.PubMed
113.
114.
Micozkadioglu H, Zumrutdal A, Torun D, et al. Low dose intradermal vaccination is superior to high dose intramuscular vaccination for hepatitis B in unresponsive hemodialysis patients. Ren Fail. 2007;29:285–8.PubMedCrossRef
115.
Propst T, Propst A, Lhotta K, Vogel W, Konig P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis. 1998;32:1041–5.PubMedCrossRef
116.
Chau KF, Cheng YL, Tsang DN, et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am J Kidney Dis. 2004;43:910–7.PubMedCrossRef
117.
Roozbeh J, Moini M, Lankarani KB, Sagheb MM, Shahpoori S, Bastani B. Low dose intradermal versus high dose intramuscular hepatitis B vaccination in patients on chronic hemodialysis. ASAIO J. 2005;51:242–5.PubMedCrossRef
118.
Bruguera M, Rodicio JL, Alcazar JM, Oliver A, Del RG, Esteban-Mur R. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine. 1990;8(Suppl):S47–9.PubMedCrossRef
119.
Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospectiverando mized study with cost-effectiveness evaluation. Nephrol Dial Transplant. 1997;12:1204–11.PubMedCrossRef
120.
Oguz Y, Doganci L, Vural A. Seroconversion rates of two different doses of hepatitis B vaccine in Turkish haemodialysis patients. Cent Eur J Public Health. 2001;9:44–5.PubMed
121.
Marangi AL, Giordano R, Montanaro A, et al. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis. 1994;23:537–42.PubMedCrossRef
122.
Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis. 2000;36:976–82.PubMedCrossRef
123.
Tong NK, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005;68:2298–303.PubMedCrossRef
124.
Evans TG, Schiff M, Graves B, et al. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic haemodialysis patients who have failed primary vaccination. Clin Nephrol. 2000;54:138–42.PubMed
125.
Grob PJ, Binswanger U, Blumberg A, et al. Thymopentin as adjuvant to hepatitis B vaccination. Results from three double-blind studies. Surv Immunol Res. 1985;4(Suppl 1):107–15.PubMed
126.
Arevalo JA, Washington AE. Cost-effectiveness of prenatal screening and for hepatitis B virus. JAMA. 1988;259(3):365–9.PubMedCrossRef
127.
Ginsberg GM, Shouval D. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity. J Epidemiol Community Health. 1992;46(6):587–94.PubMedPubMedCentralCrossRef
128.
Avazova D, Kurbanov F, Tanaka Y, Sugiyama M, Radchenko I, Ruziev D, et al. Hepatitis B virus transmission pattern and vaccination efficiency in Uzbekistan. J Med Virol. 2008;80(2):217–24.PubMedCrossRef
129.
Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986;315:209–14.PubMedCrossRef
130.
Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat. 1997;4(suppl 1):11.PubMedCrossRef
131.
Moal V, Vacher-Coponat H, Botelho E, et al. Emergence of hepatitis B infection despite antibodies to hepatitis B surface antigen: a new nosocomial risk in patients with end-stage renal disease. Transplantation. 2006;81:1358–9.PubMedCrossRef
132.
Fleming SJ, Moran DM, Cooksley WG, Faoagali JL. Poor response to a recombinant hepatitis B vaccine in dialysis patients. J Inf Secur. 1991;22:251–7.
133.
Delle VM, Caraccio V, Iberti M, et al. Hepatitis B vaccine in dialyzed patients: persistence of antibody titres after a 48-month follow-up. [Italian]. Minerva Urol Nefrol. 1996;48:47–50.
134.
Petrosillo N, Puro V, Jagger J, et al. The risks of occupational exposure and infection by human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in the dialysis setting. Italian multicenter study on nosocomial and occupational risk of infections in Dialysis. Am J Infect Control. 1995;23:278–85.PubMedCrossRef
135.
Berlyne G, Kaczmarek RG, Hamburger S, et al. Seroprevalence of antibodies to the human immunodeficiency virus in dialysis workers: results of a multi-center study. Nephron. 1992;62:441–3.PubMedCrossRef
136.
137.
Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med. 1982;307:1481–6.PubMedCrossRef
138.
139.
Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–71.PubMedCrossRef
140.
Minuk GY, Sun DF, Greenberg R, et al. Occult hepatitis B virus infection in a north American adult hemodialysis patient population. Hepatology. 2004;40:1072–7.PubMedCrossRef
141.
Metadata
Title
Clinical practice guideline management of blood borne viruses within the haemodialysis unit
Authors
Elizabeth Garthwaite
Veena Reddy
Sam Douthwaite
Simon Lines
Kay Tyerman
James Eccles
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1529-1

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue

Case report

Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report

Research article

Association of functional and structural social support with chronic kidney disease among African Americans: the Jackson Heart Study

Research article

Long-term incense use and the risk of end-stage renal disease among Chinese in Singapore: the Singapore Chinese health study

Research article

miR-10b suppresses cell invasion and metastasis through targeting HOXA3 regulated by FAK/YAP signaling pathway in clear-cell renal cell carcinoma

Case report

A case report on lipofuscin deposition in a graft biopsy two years after kidney transplantation: an insignificant bystander or a pathogenic benefactor?

Research article

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits